BRPI0406455A - Combinação farmacêutica para profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais - Google Patents

Combinação farmacêutica para profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais

Info

Publication number
BRPI0406455A
BRPI0406455A BR0406455-0A BRPI0406455A BRPI0406455A BR PI0406455 A BRPI0406455 A BR PI0406455A BR PI0406455 A BRPI0406455 A BR PI0406455A BR PI0406455 A BRPI0406455 A BR PI0406455A
Authority
BR
Brazil
Prior art keywords
cardiopulmonary
prophylaxis
cardiovascular
renal diseases
hmg
Prior art date
Application number
BR0406455-0A
Other languages
English (en)
Inventor
Axel Riedel
Josep-Maria Sendra
Josef M E Leiter
Stefan Kauschke
Michael Mark
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10335027A external-priority patent/DE10335027A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0406455A publication Critical patent/BRPI0406455A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçãO FARMACêUTICA PARA PROFILAXIA OU TERAPIA DE DOENçAS CARDIOVASCULARES, CARDIOPULMONARES, PULMONARES OU RENAIS". A presente invenção refere-se a um processo para profilaxia ou tratamento de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais pelo aperfeiçoamento da função endotelial e obtenção de uma proteção de órgãos, tecidos e vasos quando indicações, nas quais é requisitado um controle da pressão sang³ínea e um controle do nível de lipídio, particularmente para pessoas nas quais foi diagnosticada a diabetes mellitus do tipo 2 ou que existe suspeita de pré-diabete, para prevenção da diabete e pré-diabete ou para tratamento da síndrome metabólica e da resistência a insulina em pacientes com pressão sang³ínea normal. O processo abrange a administração conjunta de quantidades eficazes de telmisartan, ou um polimorfo ou seu sal, e atorvastatina. Além disso, a invenção refere-se a composições farmacêuticas apropriadas, que contêm telmisartan, ou um polimorfo ou seu sal, e atorvastatina, como preparado combinado para o emprego concomitante separado ou seq³encial na profilaxia ou tratamento dessas doenças.
BR0406455-0A 2003-01-16 2004-01-14 Combinação farmacêutica para profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais BRPI0406455A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10301371A DE10301371A1 (de) 2003-01-16 2003-01-16 Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10335027A DE10335027A1 (de) 2003-07-31 2003-07-31 Verwendung von Angiotensin II Rezeptor Antagonisten
PCT/EP2004/000174 WO2004062557A2 (de) 2003-01-16 2004-01-14 Pharmazeutische kombination aus telmisartan und atorvastatinph zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten

Publications (1)

Publication Number Publication Date
BRPI0406455A true BRPI0406455A (pt) 2005-12-06

Family

ID=32714791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406455-0A BRPI0406455A (pt) 2003-01-16 2004-01-14 Combinação farmacêutica para profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais

Country Status (21)

Country Link
US (1) US20040259925A1 (pt)
EP (1) EP1587479B1 (pt)
JP (1) JP2006515614A (pt)
KR (1) KR20050092121A (pt)
CN (1) CN1738617A (pt)
AT (1) ATE536871T1 (pt)
AU (1) AU2004204352B2 (pt)
BR (1) BRPI0406455A (pt)
CA (1) CA2513277A1 (pt)
DE (1) DE10301371A1 (pt)
EA (1) EA009874B1 (pt)
EC (1) ECSP055915A (pt)
HR (1) HRP20050654A2 (pt)
MX (1) MXPA05007103A (pt)
NO (1) NO20053837L (pt)
NZ (1) NZ541747A (pt)
PL (1) PL378225A1 (pt)
RS (1) RS20050537A (pt)
UA (1) UA84282C2 (pt)
WO (1) WO2004062557A2 (pt)
ZA (1) ZA200503542B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
CA2753318A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
ES2452019T5 (es) * 2004-11-05 2021-06-28 Boehringer Ingelheim Int Comprimido bicapa que comprende telmisartán y amlodipino
ES2454197T3 (es) * 2004-11-11 2014-04-09 Lek Pharmaceuticals D.D. Formas polimórficas de Irbesartán
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
EP2086519B1 (en) * 2006-10-30 2017-06-21 HanAll Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
US8445435B2 (en) 2007-09-28 2013-05-21 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
KR100893652B1 (ko) 2008-11-10 2009-04-17 주식회사종근당 신규한 텔미사르탄 아연염 및 그의 제조방법
CZ2008740A3 (cs) 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
CN102028682A (zh) * 2010-12-16 2011-04-27 施慧达药业集团(吉林)有限公司 一种包含替米沙坦和阿托伐他汀的复方药物制剂
SI2787993T1 (sl) * 2011-12-09 2017-04-26 Ims Medical D.O.O. Tretiranje arterijskih sten s kombinacijo raas zaviralcev in zaviralcev hmg-coa reduktaze
US20190022061A1 (en) * 2017-07-21 2019-01-24 Kieu Hoang Statins (Atorvastatin) can lower blood sugar level in diabetic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0914158T2 (sl) * 1996-04-05 2006-04-30 Takeda Chemical Industries Ltd Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
CN1651087A (zh) * 2000-04-12 2005-08-10 诺瓦提斯公司 有机化合物的联合形式
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP4585198B2 (ja) * 2002-12-27 2010-11-24 武田薬品工業株式会社 体重増加抑制剤

Also Published As

Publication number Publication date
NZ541747A (en) 2009-09-25
WO2004062557A2 (de) 2004-07-29
RS20050537A (en) 2007-09-21
EP1587479A2 (de) 2005-10-26
MXPA05007103A (es) 2005-08-26
HRP20050654A2 (en) 2006-05-31
PL378225A1 (pl) 2006-03-20
ATE536871T1 (de) 2011-12-15
AU2004204352A1 (en) 2004-07-29
KR20050092121A (ko) 2005-09-20
ZA200503542B (en) 2006-07-26
EA009874B1 (ru) 2008-04-28
WO2004062557A3 (de) 2004-09-16
US20040259925A1 (en) 2004-12-23
EP1587479B1 (de) 2011-12-14
EA200501058A1 (ru) 2006-02-24
CN1738617A (zh) 2006-02-22
JP2006515614A (ja) 2006-06-01
NO20053837L (no) 2005-08-15
AU2004204352B2 (en) 2009-07-30
ECSP055915A (es) 2006-03-01
CA2513277A1 (en) 2004-07-29
DE10301371A1 (de) 2004-08-05
UA84282C2 (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
ECSP055915A (es) Combinación farmacéutica para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales
CY1110289T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια ρινιτιδων
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ES2196917T3 (es) Amidas heteroaromaticas como inhibidores del factor xa`.
NO20060864L (no) Farmasoytisk sammensetning omfattende en kombinasjon av metformin og et statin
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
SI1587584T1 (sl) Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
NO20034986D0 (no) Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
NO20061662L (no) Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament
ATE384058T1 (de) Thiazolderivate
PA8583501A1 (es) Derivados de pirrolidona como inhibidores de maob
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
SE0200667D0 (sv) Novel use of cytokine inhibitors
JP2007506758A5 (ja) ４−（１−ベンゾフラン−３−イル−メチリデンアミノオキシ−プロポキシ）−安息香酸誘導体および線溶系の障害、血栓症の治療用のｐａｉ−１阻害剤としての関連化合物
ATE382043T1 (de) Sulfonamid-derivate als ppar-modulatoren
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
AR038305A1 (es) Composicion farmaceutica dispersable oralmente de perindopril
EP2016944A3 (en) Angiogenesis inhibitor containing a derivative of rifampicin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.